Edwards Lifesciences beats Q2 2026 estimates with non-GAAP EPS $0.78 (+16% YoY), revenue $1.7B (+14% YoY), raises 2026 sales growth guidance
https://finviz.com/stock?t=EW&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.